Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion
- PMID: 22807579
- PMCID: PMC3438283
- DOI: 10.1158/1535-7163.MCT-12-0030
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion
Abstract
The Eph family of receptors is the largest family of receptor tyrosine kinases, but it remains poorly studied in lung cancer. We aimed to systematically explore the human Eph receptors and their ligands, the ephrins, in lung adenocarcinoma. The prognostic impact of Eph receptor and ephrin gene expression was analyzed using 2 independent cohorts of lung adenocarcinoma. Gene expression profiles in lung adenocarcinoma compared with normal adjacent lung were studied in 3 independent cohorts and in cell lines. Gene expression profiles were validated with quantitative polymerase chain reaction (qPCR) and Western blotting in cell lines. Functional studies to assess the role of Eph receptor A4 (EphA4) were carried out in vitro. The biological effects of EphA4 in lung cancer cell lines were assayed following overexpression and knockdown. Of the 11 Eph receptors and 8 ephrins analyzed, only EphA4 and ephrin A1 gene expression were consistently associated with an improved outcome in patients with lung adenocarcinoma. Expression levels of EphA4 by microarray correlated well with expression levels measured by qPCR and Western blotting. EphA4 overexpression reduced cell migration and invasion but did not affect cell cycle, apoptosis, or drug sensitivity. Surprisingly, EphA4 was expressed at higher levels in cancer compared with non-cancer tissues and cell lines. EphA4 gene expression is associated with an improved outcome in patients with resected lung adenocarcinoma, possibly by affecting cancer cell migration and invasion.
©2012 AACR.
Conflict of interest statement
Figures





Similar articles
-
Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers.World J Gastroenterol. 2008 Oct 7;14(37):5650-6. doi: 10.3748/wjg.14.5650. World J Gastroenterol. 2008. PMID: 18837080 Free PMC article.
-
Sizes of interface residues account for cross-class binding affinity patterns in Eph receptor-ephrin families.Proteins. 2014 Mar;82(3):349-53. doi: 10.1002/prot.24414. Epub 2013 Oct 18. Proteins. 2014. PMID: 24105818
-
Eph-ephrin A system regulates human choriocarcinoma-derived JEG-3 cell invasion.Int J Gynecol Cancer. 2013 Mar;23(3):576-82. doi: 10.1097/IGC.0b013e3182849e36. Int J Gynecol Cancer. 2013. PMID: 23429488
-
Roles of Eph receptors and ephrins in segmental patterning.Philos Trans R Soc Lond B Biol Sci. 2000 Jul 29;355(1399):993-1002. doi: 10.1098/rstb.2000.0635. Philos Trans R Soc Lond B Biol Sci. 2000. PMID: 11128993 Free PMC article. Review.
-
A review on the role of different ephrins in glioma.Eur J Pharmacol. 2022 Feb 15;917:174588. doi: 10.1016/j.ejphar.2021.174588. Epub 2021 Oct 22. Eur J Pharmacol. 2022. PMID: 34688637 Review.
Cited by
-
Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis.Front Endocrinol (Lausanne). 2023 Aug 9;14:1162786. doi: 10.3389/fendo.2023.1162786. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37621654 Free PMC article.
-
Eph receptors and ephrins: therapeutic opportunities.Annu Rev Pharmacol Toxicol. 2015;55:465-87. doi: 10.1146/annurev-pharmtox-011112-140226. Epub 2014 Oct 3. Annu Rev Pharmacol Toxicol. 2015. PMID: 25292427 Free PMC article. Review.
-
TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis.Sci Signal. 2021 Jun 22;14(688):eabe6156. doi: 10.1126/scisignal.abe6156. Sci Signal. 2021. PMID: 34158398 Free PMC article.
-
May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?Int J Mol Sci. 2022 Dec 21;24(1):93. doi: 10.3390/ijms24010093. Int J Mol Sci. 2022. PMID: 36613532 Free PMC article. Review.
-
Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.BMC Clin Pathol. 2014 Feb 4;14(1):8. doi: 10.1186/1472-6890-14-8. BMC Clin Pathol. 2014. PMID: 24495444 Free PMC article.
References
-
- Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61:91–112. - PubMed
-
- Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004;15:419–33. - PubMed
-
- Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2009;2:1039–49. - PubMed
-
- Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009;15:4423–30. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous